COVID-19
Oxford University, which by many standards is ahead of everyone in the vaccine development world, is suggesting end of the year is possible, but being very cautious about it.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for July 22, 2020.
CanSino Biologics, along with China’s military research unit, reported early data on its Phase II trial for its COVID-19 vaccine, Ad5-nCOV.
The trial was initially scheduled for July, but in April had been postponed until October due to the pandemic. A final decision will be made in August.
Another COVID-19 vaccine candidate recently entered the races. The difference – this one is a live attenuated (weakened) virus expressing the coronavirus’s signature spike protein on its surface. And it’s delivered nasally, not a shot.
AstraZeneca’s COVID-19 vaccine candidate induced significant immune responses in the majority of patients following a single dose in a Phase I study. The preventative medication also proved to be fairly safe, study results showed.
No financial terms were disclosed, but they are apparently based on delivery time and dose volume.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for July 20, 2020.
Company shares exploded 373% at the news.
It was a surprisingly big week for clinical trial updates related to COVID-19, although there was plenty of non-COVID-19 news as well. Here’s a look.
PRESS RELEASES